ClinicalTrials.gg
CompletedNCT04966741Updated Nov 27, 2024Results posted

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

A Phase 3 interventional study of Setmelanotide in Bardet-Biedl Syndrome, POMC Deficiency Obesity and PCSK1 Deficiency Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 6 sites in 4 countries. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
2 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
14th of 16
12 · median 34
Started
2022
with 1 other
Phase 3
6 of 16
none open now
Registered
11th of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 11th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 2 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to \<6 years with obesity due to either biallelic variants of the pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) genes or Bardet-Biedl Syndrome (BBS).

Read the detailed description

Pediatric participants aged 2 to \<6 years with obesity due to either biallelic variants of the POMC, PCSK1 or LEPR genes or BBS will be enrolled into this phase 3 open-label clinical trial at one of approximately 8 clinical centers in North America, Europe, or Australia. All participants will be assigned to receive setmelanotide via daily subcutaneous (SC) injection for 1 year.

03

Conditions studied

  • Bardet-Biedl Syndrome
  • POMC Deficiency Obesity
  • PCSK1 Deficiency Obesity
  • LEPR Deficiency Obesity

Keywords

  • Bardet Biedl Syndrome
  • POMC Deficiency
  • PCSK1
  • LEPR
  • Obesity
  • Pediatric Obesity
04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants must have obesity due to either:

    1. POMC, PCSK1, or LEPR deficiency, confirmed by genetic testing demonstrating biallelic variants that are interpreted as pathogenic, likely pathogenic, or of undetermined significance (VUS) by the American College of Medical Genetics and Genomics criteria (ACMG), or
    2. BBS confirmed clinical and genetic diagnosis
  2. Age between 2 to \<6 years at the time of
  3. Obesity, defined as (BMI) ≥97th percentile for age and gender and body weight of at least 15 kilograms (kg) at the time of enrollment.
  4. Symptoms or behaviors of hyperphagia
  5. Parent or guardian of study participant is able to understand and comply with the requirements of the study (including QD injection regimen and all other study procedures) and is able to understand and sign the written consent/assent.

Key Exclusion Criteria

  1. (HbA1c) >9.0% at screening
  2. History of significant liver disease
  3. (GFR) \<60 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2)
  4. History or close family history of melanoma, or participant history of oculocutaneous albinism.
  5. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  6. Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing.
  7. Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide.
  8. Significant to any in the study drug.
  9. Inadequate hepatic function
  10. Any other uncontrolled endocrine, metabolic or medical condition(s) known to impact body weight

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Setmelanotide: PPL Group

    Participants with POMC)/PCSK1/LEPR biallelic mutations collectively referred to as PPL received setmelanotide at a dose of 0.5 milligrams (mg) per day (QD) via SC injection for 52 weeks. The dose was escalated by increments of 0.5 mg every 2 weeks, if tolerated, at the dose escalation visits (Weeks 2, 4, and 6) to a maximum dose of 0.5 to 2.0 mg QD with the maximum dose based on body weight. Following the last dose in this study, participants who were considered likely to benefit from continued setmelanotide treatment and who had completed this trial could be eligible to enter an open-label long-term extension (LTE) trial with setmelanotide.

    Drug: Setmelanotide

  • Experimental
    Setmelanotide: BBS Group

    Participants with BBS received setmelanotide at a dose of 0.5 mg QD via SC injection for 52 weeks. The dose was escalated by increments of 0.5 mg every 2 weeks, if tolerated, at the dose escalation visits (Weeks 2, 4, and 6) to a maximum dose of 0.5 to 2.0 mg QD with the maximum dose based on body weight. Following the last dose in this study, participants who were considered likely to benefit from continued setmelanotide treatment and who had completed this trial could be eligible to enter an open-label long-term extension (LTE) trial with setmelanotide.

    Drug: Setmelanotide

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52

    A "responder" was defined as a decrease from baseline to 52 weeks in the participant's BMI z-score of ≥0.2. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-scores were based on the World Health Organization's Child Growth Standards 2007 and indicated the number of standard deviations away from the mean. A Z-score of 0 was equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score (\< 0) indicated a reduction in BMI from Baseline whereas an increase of BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline up to Week 52

  2. Mean Percent Change From Baseline in BMI

    Mean percent change from baseline to Week 52 in BMI was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Mean Absolute Change From Baseline in BMI Z-score

    Mean absolute change from baseline to Week 52 in BMI Z-score was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-scores were based on the World Health Organization's Child Growth Standards 2007 and indicated the number of standard deviations away from the mean. A Z-score of 0 was equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score (\< 0) indicated a reduction in BMI from Baseline whereas an increase of BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline, Week 52

  2. Mean Change From Baseline in Percent of the 95th Percentile of BMI

    Mean change from baseline to Week 52 in percent of the 95th percentile of BMI was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. BMI Percentile-scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline, Week 52

  3. Mean Change From Baseline in Bone Age

    Mean change from baseline to Week 52 in bone age was reported. A standard bone age measurement (of the hand/wrist area) was obtained at the beginning and the end of the trial to monitor for growth related safety concerns. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline, Week 52

  4. Number of Participants With Shift From Baseline in Ages & Stages Questionnaires, Third Edition (ASQ-3)

    ASQ-3: developmental screening questionnaire that consists of 5 areas: communication, gross motor, fine motor, problem solving, and personal-social. Each area has 6 questions scored as Yes=10 points, Sometimes=5 points, and Not yet=0 points. A child can score between 0-60 points for each area with total score range: 0 to 300; higher scores are indicative of improvement. Total area score is then compared to age-adjusted standardized score cutoff (determined by developers of tool) which indicate whether child's development appears to be on schedule according to these categories: Below=Total analysis score (TAS) is below cutoff. Further assessment with professional may be needed; Monitor=TAS is close to cutoff. Provide learning activities and monitor; Above= TAS is above cutoff, and child's development appears to be on schedule. Shift from baseline for each developmental area of assessment according to these 3 outcome categories was reported. Total score was not applicable.

    Time frame: From Baseline to Week 52

  5. Change From Baseline in Body Weight

    Change from baseline to Week 52 in body weight was reported.

    Time frame: Baseline, Week 52

  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that started or worsened in intensity on or after the date of the first administration of study drug.

    Time frame: From first dose of study drug up to Week 56

  7. Number of Participants With TEAEs Graded by Severity

    A TEAE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that started or worsened in intensity on or after the date of the first administration of study drug. TEAEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) criteria. Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life Threatening; Grade 5- Death related to AE.

    Time frame: From first dose of study drug up to Week 56

07

Results

Posted Jul 10, 2024

Participant flow

Participant flow — Overall Study
MilestoneSetmelanotide: PPL GroupSetmelanotide: BBS Group
Started75
Completed65
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52

A "responder" was defined as a decrease from baseline to 52 weeks in the participant's BMI z-score of ≥0.2. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-scores were based on the World Health Organization's Child Growth Standards 2007 and indicated the number of standard deviations away from the mean. A Z-score of 0 was equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score (\< 0) indicated a reduction in BMI from Baseline whereas an increase of BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52
percentage of participantsSetmelanotide: PPL GroupSetmelanotide: BBS Group
Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 5285.7 (54.1 to 100)80.0 (28.4 to 99.5)
PrimaryMean Percent Change From Baseline in BMI

Mean percent change from baseline to Week 52 in BMI was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Mean Percent Change From Baseline in BMI
percent changeSetmelanotide: PPL GroupSetmelanotide: BBS Group
Mean Percent Change From Baseline in BMI-25.597 ± 11.4911-9.719 ± 8.8383
SecondaryMean Absolute Change From Baseline in BMI Z-score

Mean absolute change from baseline to Week 52 in BMI Z-score was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-scores were based on the World Health Organization's Child Growth Standards 2007 and indicated the number of standard deviations away from the mean. A Z-score of 0 was equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score (\< 0) indicated a reduction in BMI from Baseline whereas an increase of BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline, Week 52
Reported as:
Mean · Z-score
Mean Absolute Change From Baseline in BMI Z-score
Z-scoreSetmelanotide: PPL GroupSetmelanotide: BBS Group
Mean Absolute Change From Baseline in BMI Z-score-5.185 ± 1.8585-1.331 ± 1.2295
SecondaryMean Change From Baseline in Percent of the 95th Percentile of BMI

Mean change from baseline to Week 52 in percent of the 95th percentile of BMI was reported. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. BMI Percentile-scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline, Week 52
Reported as:
Mean · percentage relative to 95th percentile
Mean Change From Baseline in Percent of the 95th Percentile of BMI
percentage relative to 95th percentileSetmelanotide: PPL GroupSetmelanotide: BBS Group
Mean Change From Baseline in Percent of the 95th Percentile of BMI-47.595 ± 17.3280-14.462 ± 13.8571
SecondaryMean Change From Baseline in Bone Age

Mean change from baseline to Week 52 in bone age was reported. A standard bone age measurement (of the hand/wrist area) was obtained at the beginning and the end of the trial to monitor for growth related safety concerns. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline, Week 52
Reported as:
Mean · years
Mean Change From Baseline in Bone Age
yearsSetmelanotide: PPL GroupSetmelanotide: BBS Group
Mean Change From Baseline in Bone Age1.020 ± 1.07330.700 ± 0.8367
SecondaryNumber of Participants With Shift From Baseline in Ages & Stages Questionnaires, Third Edition (ASQ-3)

ASQ-3: developmental screening questionnaire that consists of 5 areas: communication, gross motor, fine motor, problem solving, and personal-social. Each area has 6 questions scored as Yes=10 points, Sometimes=5 points, and Not yet=0 points. A child can score between 0-60 points for each area with total score range: 0 to 300; higher scores are indicative of improvement. Total area score is then compared to age-adjusted standardized score cutoff (determined by developers of tool) which indicate whether child's development appears to be on schedule according to these categories: Below=Total analysis score (TAS) is below cutoff. Further assessment with professional may be needed; Monitor=TAS is close to cutoff. Provide learning activities and monitor; Above= TAS is above cutoff, and child's development appears to be on schedule. Shift from baseline for each developmental area of assessment according to these 3 outcome categories was reported. Total score was not applicable.

Time frame:
From Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Ages & Stages Questionnaires, Third Edition (ASQ-3)
ParticipantsSetmelanotide: PPL GroupSetmelanotide: BBS Group
Communication — Baseline (Above): Week 52 (Above)52
Communication — Baseline (Above): Week 52 (Monitor)00
Communication — Baseline (Above): Week 52 (Below)00
Communication — Baseline (Monitor): Week 52 (Above)00
Communication — Baseline (Monitor): Week 52 (Monitor)01
Communication — Baseline (Monitor): Week 52 (Below)00
Communication — Baseline (Below): Week 52 (Above)00
Communication — Baseline (Below): Week 52 (Monitor)00
Communication — Baseline (Below): Week 52 (Below)12
Fine Motor — Baseline (Above): Week 52 (Above)42
Fine Motor — Baseline (Above): Week 52 (Monitor)00
Fine Motor — Baseline (Above): Week 52 (Below)00
Fine Motor — Baseline (Monitor): Week 52 (Above)01
Fine Motor — Baseline (Monitor): Week 52 (Monitor)00
Fine Motor — Baseline (Monitor): Week 52 (Below)11
Fine Motor — Baseline (Below): Week 52 (Above)00
Fine Motor — Baseline (Below): Week 52 (Monitor)00
Fine Motor — Baseline (Below): Week 52 (Below)11
Gross Motor — Baseline (Above): Week 52 (Above)10
Gross Motor — Baseline (Above): Week 52 (Monitor)00
Gross Motor — Baseline (Above): Week 52 (Below)00
Gross Motor — Baseline (Monitor): Week 52 (Above)00
Gross Motor — Baseline (Monitor): Week 52 (Monitor)00
Gross Motor — Baseline (Monitor): Week 52 (Below)00
Gross Motor — Baseline (Below): Week 52 (Above)31
Gross Motor — Baseline (Below): Week 52 (Monitor)02
Gross Motor — Baseline (Below): Week 52 (Below)22
Personal - Social — Baseline (Above): Week 52 (Above)32
Personal - Social — Baseline (Above): Week 52 (Monitor)00
Personal - Social — Baseline (Above): Week 52 (Below)00
Personal - Social — Baseline (Monitor): Week 52 (Above)20
Personal - Social — Baseline (Monitor): Week 52 (Monitor)00
Personal - Social — Baseline (Monitor): Week 52 (Below)00
Personal - Social — Baseline (Below): Week 52 (Above)11
Personal - Social — Baseline (Below): Week 52 (Monitor)00
Personal - Social — Baseline (Below): Week 52 (Below)02
Problem Solving — Baseline (Above): Week 52 (Above)43
Problem Solving — Baseline (Above): Week 52 (Monitor)00
Problem Solving — Baseline (Above): Week 52 (Below)00
Problem Solving — Baseline (Monitor): Week 52 (Above)00
Problem Solving — Baseline (Monitor): Week 52 (Monitor)00
Problem Solving — Baseline (Monitor): Week 52 (Below)00
Problem Solving — Baseline (Below): Week 52 (Above)10
Problem Solving — Baseline (Below): Week 52 (Monitor)10
Problem Solving — Baseline (Below): Week 52 (Below)02
SecondaryChange From Baseline in Body Weight

Change from baseline to Week 52 in body weight was reported.

Time frame:
Baseline, Week 52
Reported as:
Mean · kilograms
Change From Baseline in Body Weight
kilogramsSetmelanotide: PPL GroupSetmelanotide: BBS Group
Change From Baseline in Body Weight-7.139 ± 5.0834-0.327 ± 2.9572
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that started or worsened in intensity on or after the date of the first administration of study drug.

Time frame:
From first dose of study drug up to Week 56
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSetmelanotide: PPL GroupSetmelanotide: BBS Group
Number of Participants With Treatment-emergent Adverse Events (TEAEs)75
SecondaryNumber of Participants With TEAEs Graded by Severity

A TEAE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that started or worsened in intensity on or after the date of the first administration of study drug. TEAEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) criteria. Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life Threatening; Grade 5- Death related to AE.

Time frame:
From first dose of study drug up to Week 56
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Graded by Severity
ParticipantsSetmelanotide: PPL GroupSetmelanotide: BBS Group
Mild25
Moderate50
Severe00
Life Threatening00
Death00

Adverse events

Collected over From first dose of study drug up to Week 56. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Setmelanotide: PPL Group0/7 (0%)0/7 (0%)7/7 (100%)
Setmelanotide: BBS Group0/5 (0%)0/5 (0%)5/5 (100%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventSetmelanotide: PPL GroupSetmelanotide: BBS Group
Skin hyperpigmentationSkin and subcutaneous tissue disorders5/74/5
NasopharyngitisInfections and infestations2/73/5
Injection site bruisingGeneral disorders1/73/5
Injection site pruritusGeneral disorders1/73/5
VomitingGastrointestinal disorders4/73/5
Upper respiratory tract infectionInfections and infestations4/70/5
FallInjury, poisoning and procedural complications4/70/5
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/71/5
InfluenzaInfections and infestations0/72/5
PyrexiaGeneral disorders2/72/5

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Setmelanotide: PPL GroupSetmelanotide: BBS GroupTotal
Mean3.4 ± 0.533.8 ± 1.303.6 ± 0.90
Sex: Female, Male
Sex: Female, Male(Participants)Setmelanotide: PPL GroupSetmelanotide: BBS GroupTotal
Female235
Male527
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Setmelanotide: PPL GroupSetmelanotide: BBS GroupTotal
Hispanic or Latino101
Not Hispanic or Latino459
Unknown or Not Reported202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Setmelanotide: PPL GroupSetmelanotide: BBS GroupTotal
Race — American Indian or Alaska Native000
Race — Asian011
Race — White347
Race — Other202
Race — Unknown or Not Reported202
Body Mass Index (BMI) Z-score
Body Mass Index (BMI) Z-score(z-score)Setmelanotide: PPL GroupSetmelanotide: BBS GroupTotal
Mean10.749 ± 3.84004.233 ± 1.07428.034 ± 4.4408
BMI
BMI(kg/m^2)Setmelanotide: PPL GroupSetmelanotide: BBS GroupTotal
Mean34.347 ± 7.067323.716 ± 3.518429.918 ± 7.8559
08

Study locations

6 sites
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Columbia University Medical Center, Division of Pediatric Endocrinology, Diabetes and Metabolism
    New York, New York 10032, United States
  • Marshfield Clinic Research Foundation
    Marshfield, Wisconsin 54449, United States
  • Sydney Children's Hospital
    Randwick, NSW 2031, Australia
  • Hospital Infantil Niño Jesus
    Madrid, 28009, Spain
  • Addenbrooke's Hospital, Wellcome Trust-MRC Institute of Metabolic Science
    Cambridge, CB2 0QQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Sep 2023, 18 months.

Results were first posted in Jul 2024, 9 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 18 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
Jul 19, 2021
StartActual
Mar 8, 2022
Primary completionActual
Sep 18, 2023
CompletionActual
Nov 8, 2024
Results first posted
Jul 10, 2024
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04966741
Responsible party
Sponsor
First posted
Jul 19, 2021
Start date
Mar 8, 2022
Primary completion
Sep 18, 2023
Completion
Nov 8, 2024
Results posted
Jul 10, 2024
Last update
Nov 27, 2024

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion